Transplantation, AutologousHematopoietic Stem Cell TransplantationStem Cell TransplantationTransplantation, HomologousBone Marrow TransplantationLiver TransplantationTransplantation ConditioningMultiple MyelomaKidney TransplantationMelphalanPeripheral Blood Stem Cell TransplantationCombined Modality TherapyTreatment OutcomeGraft SurvivalHematopoietic Stem Cell MobilizationHeart TransplantationAntineoplastic Combined Chemotherapy ProtocolsBlood Transfusion, AutologousSalvage TherapyLymphoma, Non-HodgkinLung TransplantationRemission InductionStem CellsBone Marrow PurgingCell TransplantationRecurrenceCarmustineCyclophosphamideHematopoietic Stem CellsEtoposideDisease-Free SurvivalHodgkin DiseaseAntigens, CD34Whole-Body IrradiationGraft vs Host DiseaseRetrospective StudiesOrgan TransplantationSurvival AnalysisSurvival RateCytarabineGranulocyte Colony-Stimulating FactorLeukapheresisGraft RejectionBusulfanMyeloablative AgonistsTime FactorsTissue DonorsPancreas TransplantationIslets of Langerhans TransplantationImmunosuppressive AgentsFollow-Up StudiesHematologic NeoplasmsTransplantation ImmunologyVincristineTransplantationTransplantation ChimeraThalidomideThiotepaPrognosisTransplantation, IsogeneicMesenchymal Stem Cell TransplantationDexamethasoneCord Blood Stem Cell TransplantationLymphomaBone MarrowPrednisoneAntineoplastic Agents, AlkylatingCells, CulturedTransplantation, HeterotopicLiving DonorsDoxorubicinAntibodies, Monoclonal, Murine-DerivedBlood Component RemovalFeasibility StudiesBone Marrow CellsNeoplasm, ResidualHeart-Lung TransplantationCell SeparationLeukemia, Myeloid, AcuteHematopoiesisImmunosuppressionGraft vs Tumor EffectProspective StudiesHistocompatibility TestingTransplantation ToleranceAntibodies, MonoclonalTissue and Organ ProcurementIdarubicinAmyloidosisMyelodysplastic SyndromesT-LymphocytesSkin TransplantationLeukemiaPostoperative ComplicationsAntineoplastic AgentsCell DifferentiationFetal Tissue TransplantationFlow CytometryTransplantation, HeterologousLiver Failure